236 related articles for article (PubMed ID: 33172886)
1. Low-dose or no aspirin administration in acute-phase Kawasaki disease: a meta-analysis and systematic review.
Chiang MH; Liu HE; Wang JL
Arch Dis Child; 2021 Jul; 106(7):662-668. PubMed ID: 33172886
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
[TBL] [Abstract][Full Text] [Related]
3. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis.
Zheng X; Yue P; Liu L; Tang C; Ma F; Zhang Y; Wang C; Duan H; Zhou K; Hua Y; Wu G; Li Y
PLoS One; 2019; 14(5):e0217274. PubMed ID: 31117119
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroids for the treatment of Kawasaki disease in children.
Wardle AJ; Connolly GM; Seager MJ; Tulloh RM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011188. PubMed ID: 28129459
[TBL] [Abstract][Full Text] [Related]
6. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
8. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
Dhanrajani A; Chan M; Pau S; Ellsworth J; Petty R; Guzman J
Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1536-1540. PubMed ID: 29287309
[TBL] [Abstract][Full Text] [Related]
9. Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial.
Wu Y; Hu L; Xie X; Li W; Wang Y; Zhang L; Huang P; Li F; Li J; Xia S; Yuan J; Li M; Wang Z; Zhang X
Am Heart J; 2024 Jul; 273():1-9. PubMed ID: 38508571
[TBL] [Abstract][Full Text] [Related]
10. Neutropenia after intravenous immunoglobulin therapy is associated with coronary artery lesions in children with Kawasaki disease: a case control study.
Wang Z; Weng F; Li C; Shi H; Tang Z; Qiu H; He Y; Wu R; Chu M
BMC Pediatr; 2018 Feb; 18(1):76. PubMed ID: 29466965
[TBL] [Abstract][Full Text] [Related]
11. [Kawasaki disease: what you need to know].
Bajolle F; Laux D
Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
[TBL] [Abstract][Full Text] [Related]
12. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
Kuo HC; Guo MM; Lo MH; Hsieh KS; Huang YH
BMC Pediatr; 2018 Jun; 18(1):200. PubMed ID: 29933749
[TBL] [Abstract][Full Text] [Related]
14. Infections and Kawasaki disease: implications for coronary artery outcome.
Benseler SM; McCrindle BW; Silverman ED; Tyrrell PN; Wong J; Yeung RS
Pediatrics; 2005 Dec; 116(6):e760-6. PubMed ID: 16322132
[TBL] [Abstract][Full Text] [Related]
15. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
Newburger JW; Sleeper LA; McCrindle BW; Minich LL; Gersony W; Vetter VL; Atz AM; Li JS; Takahashi M; Baker AL; Colan SD; Mitchell PD; Klein GL; Sundel RP;
N Engl J Med; 2007 Feb; 356(7):663-75. PubMed ID: 17301297
[TBL] [Abstract][Full Text] [Related]
17. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan.
Suzuki T; Michihata N; Hashimoto Y; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
Eur J Pediatr; 2024 Jan; 183(1):415-424. PubMed ID: 37917176
[TBL] [Abstract][Full Text] [Related]
18. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
19. Tricuspid regurgitation in acute phase of Kawasaki disease associated with intensive care unit admission.
Lin YJ; Lin IC; Yu HR; Kuo HC; Yang KD; Chang WC; Liang CD; Liu SF; Kuo HC
Pediatr Cardiol; 2013 Feb; 34(2):250-5. PubMed ID: 22810044
[TBL] [Abstract][Full Text] [Related]
20. Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.
Zheng X; Li J; Yue P; Liu L; Li J; Zhou K; Hua Y; Li Y
PLoS One; 2021; 16(3):e0248812. PubMed ID: 33764989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
